Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILRB4 STAR-T Cells in R/R AML and CMML
NCT05548088Phase 1Completed
- Sponsor
- Peking University People's Hospital
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LILRB4 STAR-T in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), sponsored by Peking University People's Hospital. Primary endpoints: Dose-Limiting Toxicity at 12 months, Adverse Events at 12 months and 3 more. Started May 2023; status: completed.
02
Drugs
LILRB4 STAR-T
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05548088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548088.